Rivaroxaban

16 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Hematology-Oncology

Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS Trial

By MedXY|Jul 7, 2026

This article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.

Diabetes & Endocrinology

Rivaroxaban

Latest news

Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS Trial

Safety and Effectiveness of Rivaroxaban Thromboprophylaxis in ACTH-Dependent Cushing Syndrome

Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

VOYAGER-PAD Insight: Prior Revascularization History Mandates More Aggressive Antithrombotic Therapy

Low-Dose Rivaroxaban Fails to Significantly Reduce Left Ventricular Thrombosis in Anterior STEMI: Results of the APERITIF Trial

Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial

Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

Age-Stratified Outcomes of Rivaroxaban Monotherapy in Atrial Fibrillation with Stable Coronary Artery Disease: Insights from the AFIRE Trial

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

Extended Rivaroxaban Therapy in Cancer Patients with Low-Risk Pulmonary Embolism: 6 OR 18 Months？

Evaluating Aspirin Plus Rivaroxaban versus Rivaroxaban Alone to Prevent Venous Stent Thrombosis in Post-Thrombotic Syndrome: Insights from the ARIVA Trial

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial